SEC Form 4
Intellia Therapeutics, Inc (NTLA) insider trading
In the 12 months to Oct 24, 2026, 2 NTLA insiders reported open-market sales of $1.2M across 3 filings; one director bought $1.4M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $1.2M
- 3 filings · 2 insiders
- Open-market purchases
- $1.4M
- 1 filing · Fred E. Cohen, Director
- Pre-arranged sales (10b5-1)
- 3 of 3
- All $1.2M sold was pre-arranged
Who traded NTLA, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
NTLA daily close from Oct 24, 2025 to Oct 23, 2026, between $8.04 and $25.60, last $11.21. 3 sale and 1 purchase filings by 3 insiders, marked at their filing dates. Fred E. Cohen, Director: bought $1.4M across 1 filing, first filed Jan 7, 2026, last Jan 7, 2026. John M. Leonard, President and CEO: sold $1.1M across 2 filings, first filed Dec 12, 2025, last Aug 24, 2026. Edward J. Dulac III, EVP, Chief Financial Officer: sold $84.2K across 1 filing, first filed Jul 6, 2026, last Jul 6, 2026.
Largest mark · tap a row for others
Fred E. Cohen · Director
Purchase $1,402,500
150,000 shares at $9.35 avg
Filed Jan 7, 2026 · traded Jan 5
Close on filing date $10.13
Fred E. Cohen · Director
Director
$1.4M boughtJohn M. Leonard · President and CEO
President and CEO
$1.1M soldEdward J. Dulac III · EVP, Chief Financial Officer
EVP, Chief Financial Officer
$84.2K soldHas Intellia Therapeutics, Inc's CEO sold stock?
Yes. John M. Leonard (CEO) sold 110,821 shares ($1.1M) between Dec 2025 and Aug 2026, all under a pre-arranged 10b5-1 plan.
Open-market trades
4 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Fred E. Cohen | Director | — | $1.4M | 1 | — | |
| John M. Leonard | President and CEO | $1.1M | — | 2 | 100% of sales | |
| Edward J. Dulac III | EVP, Chief Financial Officer | $84.2K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | John M. Leonard President and CEO | SalePre-arranged (10b5-1) | 22,675 | $12.65 | $286.8K | 1,147,064 | |
traded | Edward J. Dulac III EVP, Chief Financial Officer | SalePre-arranged (10b5-1) | 4,677 | $18.00 | $84.2K | 156,286 | |
traded | Fred E. Cohen Director | Purchase | 150,000 | $9.35 | $1.4M | 207,453 | |
traded | John M. Leonard President and CEO | SalePre-arranged (10b5-1) | 88,146 | $9.49 | $836.4K | 1,044,283 |
GET /stocks/filings/vX/form-4?tickers=NTLA&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"NTLA"
],
"issuer_cik": "0001652130",
"owner_cik": "0001563584",
"accession_number": "0001193125-26-363567",
"form_type": "4",
"filing_date": "2026-08-24",
"period_of_report": "2026-08-20",
"issuer_name": "Intellia Therapeutics, Inc.",
"issuer_trading_symbol": "NTLA",
"owner_name": "LEONARD JOHN M",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 19890,
"transaction_price_per_share": 12.6,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1149849,
"transaction_value": 250614,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price."
}
]
},
{
"tickers": [
"NTLA"
],
"issuer_cik": "0001652130",
"owner_cik": "0001563584",
"accession_number": "0001193125-26-363567",
"form_type": "4",
"filing_date": "2026-08-24",
"period_of_report": "2026-08-20",
"issuer_name": "Intellia Therapeutics, Inc.",
"issuer_trading_symbol": "NTLA",
"owner_name": "LEONARD JOHN M",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-21",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2785,
"transaction_price_per_share": 13,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1147064,
"transaction_value": 36205,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 28 records
- Option exercises2 records
- Tax withholding (sold to cover)12 records
- Grants and awards14 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for NTLA every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.